| Issue |
Section |
Title |
File |
| Vol 10, No 1 (2014) |
REVIEW |
ANDROGEN DEPRIVATION THERAPY WITH LUTEINIZING HORMONE-RELEASING HORMONE ANTAGONISTS FOR PROSTATE CANCER: BEST DISEASE CONTROL WITH A LOWER RISK OF SIDE EFFECTS. RESULTS OF ANALYSIS OF 6 COMPARATIVE RANDOMIZED PHASE III TRIALS OF DEGARELIX AND LUTEINIZIN |
(Rus)
|
| Vol 9, No 2 (2013) |
REVIEW |
CURRENT POSSIBILITIES OF DRUG THERAPY FOR CASTRATION-RESISTANT PROSTATE CANCER |
(Rus)
|
| Vol 8, No 1 (2012) |
CLINICAL CASE |
TESTICULAR CAPILLARY HEMANGIOMA: DESCRIPTION OF A CASE |
(Rus)
|
| Vol 11, No 1 (2015) |
REVIEW |
Noninterventional studies of depot formulations of LHRH analogues for prostate cancer in routine clinical practice. The launch of an observational program to assess the use of Eligard 45 mg in Russia |
(Rus)
|
| Vol 11, No 2 (2015) |
PROSTATE CANCER |
Predictors of overall survival in patients with metastatic castration-resistant prostate cancer |
(Rus)
(Eng)
|
| Vol 12, No 2 (2016) |
PROSTATE CANCER |
Intermediate results of the observational program on the Eligard (45 mg) administration in the clinical practice |
(Rus)
(Eng)
|
| Vol 12, No 4 (2016) |
DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS. RENAL CANCER |
Molecular genetic diagnostics of clear cell renal cell carcinoma |
(Rus)
|
| Vol 13, No 2 (2017) |
DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS. PROSTATE CANCER |
Final results of the prospective multicenter observational program RU-EGD-NI-001 for evaluation of efficacy and tolerability of the 6-month depot Eligard 45 mg in patients with advanced prostate carcinoma in routine clinical practice of uro-oncologists in the Russian Federation |
(Rus)
|
| Vol 13, No 3 (2017) |
REVIEW |
Possibilities of optimization of the second line targeted therapy for metastatic renal cell carcinoma |
(Rus)
|
| Vol 13, No 3 (2017) |
REVIEW |
Radium-223 in treatment of castration-resistant prostate cancer with skeletal metastases |
(Rus)
|
| Vol 14, No 1 (2018) |
DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS. PROSTATE CANCER |
Safety of enzalutamide in patients with progressive castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy: a phase II, multicenter, single-arm, open-label study |
(Rus)
|
| Vol 14, No 2 (2018) |
CONGRESSES AND CONFERENCES |
33rd Annual Congress of the European Association of Urology in 2018: Review of oncological topics |
(Rus)
|
| Vol 14, No 3 (2018) |
REVIEW |
SEQUENTIAL THERAPY OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: NEW POSSIBILITIES |
(Rus)
|
| Vol 15, No 2 (2019) |
REVIEW |
Neuroendocrine tumors of the urinary system: literature review |
(Rus)
|
| Vol 14, No 4 (2018) |
DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS. RENAL CANCER |
Renal cell carcinoma: What’s new in 2018 |
(Rus)
|
| Vol 16, No 4 (2020) |
DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS. PROSTATE CANCER |
Efficacy and safety of radium-223 in routine clinical practice |
(Rus)
|
| Vol 17, No 2 (2021) |
DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS. PROSTATE CANCER |
Luteinizing hormone-releasing hormone agonists for prostate cancer patients: routine clinical practice of Russian cancer urologists |
(Rus)
|
